RE: Telegram21 Jul 2020 19:41
This guy. Worked on that rto why bring him out of retirement now? DIRECTORATE CHANGE
OKYO Pharma Limited ("OKYO" or the "Company") today announces that John Brancaccio has been appointed as a non-executive director of the company with immediate effect. Gregor MacRae is simultaneously standing down as a director of the Company with immediate effect.
Mr Brancaccio (aged 72) is a retired certified accountant. Mr Brancaccio graduated from Selton Hall University in New Jersey with a BA in Accountancy prior to joining Touche Ross & Co in 1970. Having attained the position of audit supervisor, Mr Brancaccio went into industry in 1974.
Most recently, prior to his retirement in 2017, Mr Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc. overseeing a portfolio of companies in the medical device area and managing the private financing rounds for each company. This portfolio was in excess of $100 million in invested funds.
Mr Brancaccio has extensive public company non-executive experience and is currently a member of the boards of directors of Rasna Therapeutics, Inc., Hepion Pharmaceuticals, Inc., and Cardiff Oncology, Inc.
John will chair the Audit and Risk Committee of the Board (which also comprises Willy Simon) and will sit as a member of the Remuneration Committee (which also comprises Willy Simon as chairman).
Willy Simon, Chairman of OKYO, said "We are delighted that John has joined the Board of OKYO. His expertise will be of great value to us. He is a great addition to the Board at a very important time for the group. I thank Gregor for his contribution to the Board and the Company and wish him well in his other interests".
Sign In
Follow the stocks
